Ga-68-DOTATOC, SomaKit TOC (edotreotide) is a small molecule pharmaceutical. Edotreotide was first approved as Ga-68-DOTATOC on 2016-12-08. It has been approved in Europe to treat neuroendocrine tumors and radionuclide imaging. It is known to target somatostatin receptor type 2.
|Trade Name||SomaKit TOC|
|Indication||neuroendocrine tumors, radionuclide imaging|
|Drug Class||Peptides: inhibition of growth hormone release|